Close Menu

NEW YORK – Molecular diagnostic company Co-Diagnostics announced Thursday that it has entered into an agreement with institutional investors for a $4.2 million registered direct offering.

The offering is for the purchase of 470,000 shares of common stock at the purchase price of $9.00 per share, with the closing expected to occur on or before March 2, 2020.

The exclusive lead placement agent for the offering is HC Wainwright. Maxim Group is acting as co-placement agent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.